

CURRICULUM VITAE

Day prepared : November 30, 2016

First Name : Ioannis

Family Name: Kotsianidis

Father's Name: Dimitrios

Mather's Name: Maria

Date of Birth: September 18, 1968

Place of Birth : Thessaloniki

Home address: Evgenidi 8

Alexandroupolis, 68100

Phone: 0030 2551030320

0036948483319

E-mail: i.kotsianidis@med.duth.gr

CURRENT POST

27.06.16-to date: **Professor of Hematology**, Democritus Thrace University, School of Medicine. Head of the Hematology department, University Hospital of Alexandroupolis, Greece.

ADDRESS

Department of Hematology
University Hospital of Alexandroupolis
Dragana, Alexandroupolis, Greece
tel: 0030 25510 30320
fax: 0030 25510 76154
e-mail: ikotsian@med.duth.gr

QUALIFICATIONS

MD (Ptychion Iatrikis, grade 8 out of 10)	Oct 1993	Aristotelion University, Thessaloniki, Greece
Board Certified in Hematology	Feb 2003	Alexandroupolis, Greece
PhD (excellent)	Dec 2003	Democritus Thrace University, School of Medicine, Alexandroupolis, Greece

PREVIOUS POSTS

07/13-to date **Associate Professor of Hematology**, Department of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece

04/09-07/13 **Assistant Professor of Hematology**, Department of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece

05/05-04/09: **Lecturer of Hematology**, Department of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece

03/03-05/05: **Clinical Research Fellow**, Department of Hematology, Faculty of Medicine –ICSTM, Hammersmith Hospital, London UK

01/99-01/03: **Fellow in Hematology**, Department of Hematology Alexandroupolis Hospital, Medical School, Democritus University of Thrace, Alexandroupolis, Greece

03/97-11/98: **Resident in Internal Medicine**, Second Propedeutic department of Internal medicine, Aristotle University of Thessaloniki, Hippokrateion Hospital, Thessaloniki, Greece

11/96-3/97: **General Practitioner, (private practice)**, St. Luke's Hospital, Thessaloniki, Greece

04/95-10/96: **General Practitioner**, Hellenic Army, Signal Corps

11/94-03/95: **Resident in Internal Medicine**, Department of Internal medicine, General Hospital of Katerini, Katerini, Greece

06/93-11/94: **General Practitioner**, Health Centre of Ellasona, Larisa, Greece

CLINICAL EXPERIENCE

I have extensive experience in the management of patients with haematological malignancies, primarily, patients with myelodysplastic syndromes (MDS) and lymphoproliferative disorders (LPD). My clinical responsibilities comprise patient management and follow up on the ward (daily) and outpatient clinics (thrice weekly). I am also Head of the Laboratory of Hematology and Immunohematology and in charge of the clinical immunophenotyping service of Hematology Department of University Hospital of Alexandroupolis. More analytically:

Training in General Medicine

I was trained for 2 years in Internal Medicine at Hippokration General Hospital, one of the largest hospitals in Balkans (approximately 1000 beds). During this period I gained valuable experience in General Medicine, Nephrology, Cardiology, Rheumatology, Gastroenterology and Endocrinology.

Training in Hematology

My entire 4-year training in Hematology took place at the Department of Hematology of the Medical School of University Hospital of Thrace; a 350-bed supra-regional hospital with a 15-bed Hematology Department.

General Hematology and haematological malignancies

I have gained significant experience in the management of haematologic malignant and non-malignant diseases with my active involvement in the investigation, treatment plan and management of the patients. I also followed up patients with haematological disorders in the outpatient clinics (twice weekly).

Autologous transplantation

The last 10 years the Department has been performing autologous PBSC and bone marrow transplantations in haematological malignancies (multiple myeloma and lymphoma). I was responsible for enumeration the CD34⁺ cell dose in the apheresis products by using flow cytometry and I was actively involved with the management of the transplant patients during while on the ward as well as with their follow up in the outpatient clinics (once weekly).

Coagulation

I was trained in the coagulation laboratory attending conventional and molecular methods for the investigation of hemorrhagic and thrombophilic disorders. I also followed up patients with the above disorders in the outpatient clinics (once weekly).

SCIENTIFIC EXPERIENCE

May 2005 – to date. Democritus University of Thrace

My current research interests are focused on the immune regulation and cell signaling interactions of normal and malignant hematopoiesis. I extensively studied the role of T-regulatory cells in the pathogenesis of myelodysplastic syndromes and idiopathic pulmonary fibrosis. Additionally, in collaboration with Prof Anastasios Karadimitris' laboratory at Hammersmith hospital, I investigated the role of the CD1d molecule and invariant NKT cells in the pathogenesis of multiple myeloma. All of the above projects have been completed successfully, and have been published in high ranking medical journals. I am currently

studying the signaling networks of the leukemic progenitors and immune subsets in MDS patients at the single cell level. Moreover, in collaboration with the department of Pneumonology I published pioneering research regarding the role of Tregs in idiopathic pulmonary fibrosis, whereas I also have fruitful collaboration with the Cardiology, Nephrology, Orthopedics, and internal Medicine.

March 2003 – May 2005: Hammersmith Hospital, Imperial College London. Clinical Research Fellow (recipient of an LRF Clinical Research Fellowship and a Fluka Fellowship).

During my training in the laboratory of Prof Irene Roberts and Prof Anastasios Karadimitris, I studied the role of NKT cells in alloresponses in vitro and in the regulation of hematopoiesis and osteopoiesis using both in vivo and in vitro models. Moreover, I investigated the interaction of CD1d molecule with the wnt- β -catenin axis and I participated and in the discovery of the mutation responsible for the inherited paroxysmal nocturnal hemoglobinuria.

December 2000 – December 2003: Democritus University of Thrace.

I accomplished a 3 year medical thesis studentship entitled "Immunophenotypic study of normal human bone marrow with particular emphasis on CD1d expression on hematopoietic progenitors" under the supervision of Professor C. Tsatalas, Department of Hematology, Medical School, Democritus University of Thrace, Alexandroupolis. Parallel to my thesis I have been studying platelet activation in potential prothrombotic states, such as acute pancreatitis, thalidomide treatment in multiple myeloma and unstable/stable angina.

Research funding

Total budget; Starting date; Duration (months); Source of funding; Title; Position

1. £75,000; December 2003; 15; Leukemia Research Foundation/project grant; Expression and function of CD1d in multipotential haemopoietic stem cells; Clinical Research Fellow.
2. £150,000; June 2005; 32; Leukemia Research Foundation/project grant; Concerted regulation of haemopoiesis and osteopoiesis by NKT cells; Collaborating researcher.
3. £126,000; November 2006; 30; Leukemia Research Foundation/project grant; CD1d, NKT cells and GSL in the pathogenesis of multiple myeloma; Collaborating researcher.
4. £110,000; November 2007; 24; Kay Kendall Leukaemia Fund/project grant; Role of CD1d in marginal zone B cell development; Collaborating researcher.
5. €15,000; December 2007; 24; Hellenic Thoracic Society/Fellowship; The role of naturally occurring CD4⁺CD25^{high}Foxp3⁺ regulatory T-cells in the pathogenesis of idiopathic interstitial pneumonias; Co-investigator.
6. €25,000; May 2008; 16; Novartis Hellas/project grant; Study of CD1d expression and function in normal B-cell development and B lymphoproliferative disorders. Implications in pathophysiology, diagnosis, and prognosis of B-cell lymphomas; Principal investigator.

7. €12,000; February 2009; 24; Hellenic Ministry of Health and Social Solidarity/project grant; The dual role of naturally occurring CD4+ CD25+ Foxp3+ T regulatory cells in the autoimmune manifestations and pathogenesis of Myelodysplastic Syndromes and Myeloproliferative Disorders; Principal investigator.
8. €15,000; October 2010; 24; Hellenic Thoracic Society/Fellowship; Exploring the immunomodulating effects of Clarithromycin on patients with bronchiectasis using exhaled breath condensate, blood and sputum specimens; Collaborating researcher.
9. €20,000; May 2010; 24; Roche Hellas/project grant; Effects of JAK2V617F point mutation in osteoclast function in patients with chronic myeloproliferative neoplasms; Principal investigator.
10. €25,000; December 2011; 18; Gilead Hellas/project grant; Investigation of the signaling profiles of CD34+ cells in MDS patients during treatment with hypomethylating agents; Principal investigator.
11. €10,000, July 2014; 24; TEVA Hellas/project grant; Resistance to hypomethylating agents: investigation of the role of molecules implicated in the metabolism and intracellular transport of hypomethylating agents in Myelodysplastic syndromes; Principal investigator.
12. €50,000, September 2015, 36, Celgene/project grant, Epigenetic Regulation Of Hematopoietic Stem/Progenitor Cell (HSPC) Signaling Networks In Myelodysplastic Syndrome patients treated with azacitidine. Principal investigator.

Clinical trials

Starting date; Duration (months); Source of funding; Title; Position

1. Oct 2007; 36, Genesis; «Retrospective and prospective observational study for the management of supportive care of patients with Non-Hodgkin's lymphoma (NHL) treated with CHOP-14 ή 21 (with or without Rituximab)» IMPACT; Principal investigator.
2. July 2011; 7; Janssen, "Retrospective evaluation of bortezomib retreatment in patients in first relapse after first line treatment with bortezomib"; Principal investigator.
3. November 2011; 144; GlaxoSmithKline; "An open randomized study of the combination of M α Ofatumumab plus Bendamustine compared to monotherapy with Bendamustine in B-cell low grade non Hodgkin lymphomas refractory to Rituximab or Rituximab containing regimens during or into 6 months of treatment start"; Co-investigator.
4. March 2012; 46; Roche Hellas; "Non interventional, observational, phase IV trial of safety evaluation of Rituximab (MabThera) in combination with chemotherapy in the treatment of patients with B cell chronic lymphocytic leukemia"; Co-investigator.
5. April 2012; 16; Genesis Hellas; "RETRO-AZA-MDS-001: A retrospective, non interventional study of evaluation of azacitidine treatment in intermediate – 2 and high risk (according to International Prognostic Scoring System) Myelodysplastic syndrome patients"); Co-investigator.

6. March 2013; 56; Novartis Hellas; "PROMETHEUS: Non interventional, prospective open study for the evaluation of liver iron overload as assessed by MRI T2*, in low/intermediate-1 risk MDS patients treated with deferasirox"; Principal investigator.
7. July 2015; 60; Celgene; "A prospective non-interventional post-authorization safety study (PASS), designed as a disease registry of patients with transfusion dependent IPSS low or intermediate-1-risk myelodysplastic syndromes (MDS) and isolated del(5q) "; Principal investigator.
8. October 2015; 60; Roche Hellas; "A multicenter, single arm, non-interventional, observational study of Obinutuzumab to evaluate efficacy, safety and cost of disease management in patients with chronic lymphocytic leukemia and comorbidities in Greece". Principal investigator.

Published work

Full papers in Greek journals: 11
 Full papers in Medline-indexed journals (Medline-indexed): 61
 Full papers in Medline-indexed journals (non-indexed): 4
 Chapters in conference supplements (full text): 17
 Citations: (Scopus: 757, Hazard's: 993)
 H index (Scopus: 14, Hazard's: 15)

Report of scholarship

Peer Reviewed Publications in Medline indexed journals

1. Tsatalas C, Margaritis D, Kaloutsi V, Martinis G, **Kotsianidis I**, Bourikas G. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with Fludarabine. *Acta Haematologica* 2001;105:106-108. (IF:1,352)
2. Tsatalas C, Martinis G, Margaritis D, Spanoudakis E, **Kotsianidis I**, Karpouzis A, Bourikas G. Long-term remission of recalcitrant tumour-stage mycosis fungoides following chemotherapy with pegylated liposomal doxorubicin. *J Eur Acad Dermatol Venereol*. 2003 Jan;17(1):80-2. (IF:1,437)
3. C. Tsatalas, D. Margaritis, D. Pantelidou, **I. Kotsianidis**, A.J. Karayiannakis, E. Spanoudakis, Z. Kartasis, V. Kaloutsi, A. Polychronidis, I. Manavis, G. Bourikas. Splenectomy for massive splenic infarction unmasks paroxysmal nocturnal hemoglobinuria. *Acta Haematol* 110(4):193, 2003. (IF:1,352)
4. A. Karpouzis, C. Tsatalas, E. Sivridis, **I. Kotsianidis**, D. Margaritis, C. Kouskoukis, G. Bourikas. Acquired reactive perforating collagenosis associated with evolving myelodysplastic syndrome. *Austral J Dermatol* 45(1):51, 2004. (IF:0,973)
5. Mimidis K, Papadopoulos V, **Kotsianidis J**, Filippou D, Spanoudakis E, Bourikas G, Dervenis C, Kartalis G. Alterations of platelet function, number and indexes during acute pancreatitis. *Pancreatology* 2004;4(1):22-7. (IF:2,522)
6. C. Tsatalas, E. Spanoudakis, D. Pantelidou, D. Margaritis, **I.Kotsianidis**, P. Chalkia, G. Tripsianis, I. Basdiara, Z. Kartasis, A. Karakolios, G.Bourikas. Amifostine Stimulates The

Formation Of Haematopoietic Bone Marrow Progenitors From B-cell Chronic Lymphocytic Leukemia (B-CLL). *Acta Haematol.* 2004;112(3):136-40. (IF:1,352)

7. Politou M, Karadimitris A, Terpos E, **Kotsianidis I**, Apperley JF, Rahemtulla A. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. *Leuk Res.* 2006 Feb;30(2):240-1. (IF:2,561)

8. Patterson S, **Kotsianidis I**, Almeida A, Politou M, Rahemtulla A, Matthew B, Schmidt RR, Cerundolo V, Roberts IA, Karadimitris A. Human invariant NKT cells are required for effective in vitro alloresponses. *J Immunol.* 2005 Oct 15;175(8):5087-94. (IF:6,068)

9. **Kotsianidis I**, Silk JD, Spanoudakis E, Patterson S, Almeida A, Schmidt RR, Tsatalas C, Bourikas G, Cerundolo V, Roberts IA, Karadimitris A. Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. *Blood.* 2006 Apr 15;107(8):3138-44. (IF:10,896)

10. Matsouka P, Pagoni M, Zikos P, Giannakoulas N, Apostolidis I, Asprogeraka T, Arvanitopoulou E, Spanoudakis E, **Kotsianidis I**, Tsatalas K, Papaioannou M, Marinakis T, Skandali A, Viniou N, Yataganas X, Bakiri M. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology. *Ann Hematol.* 2006 Apr;85(4):250-6. (IF:2,352)

11. Almeida AM, Murakami Y, Layton DM, Hillmen P, Sellick GS, Maeda Y, Richards S, Patterson S, **Kotsianidis I**, Mollica L, Crawford DH, Baker A, Ferguson M, Roberts I, Houlston R, Kinoshita T, Karadimitris A. Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. *Nat Med.* 2006 Jul;12(7):846-51. (IF:26,382)

12. Froudarakis ME, Papadaki HA, Klimathianaki M, Damianaki A, Pougounias M, **Kotsianidis I**, Astoul P. Thoracoscopic talc poudrage decreases T-lymphocytes in the peripheral blood. *Respir Med.* 2007 Jun;101(6):1212-7. (IF:2,475)

13. Stakos DA, **Kotsianidis I**, Tziakas DN, Spanoudakis E, Chalikias G, Bourikas G, Katsaris G, Boudoulas H. Leukocyte activation after coronary stenting in patients during the subacute phase of a previous ST-elevation myocardial infarction. *Coron Artery Dis.* 2007 Mar;18(2):105-10. (IF:1,556)

14. Tzouvelekis A, **Kotsianidis I**, Steiropoulos P, Bouros D. Role of CD146 in detection of apoptotic circulating endothelial cells in obstructive sleep apnea. *Am J Respir Crit Care Med.* 2007 Jun 15;175(12):1346-1347. (IF:9,074)

15. Manola KN, Georgakakos VN, Margaritis D, Stavropoulou C, Panos C, **Kotsianidis I**, Pantelias GE, Sambani C. Disruption of the ETV6 gene as a consequence of a rare translocation (12;12)(p13;q13) in treatment-induced acute myeloid leukemia after breast cancer. *Cancer Genet Cytogenet.* 2008 Jan 1;180(1):37-42. (IF:1,559)

16. Spanoudakis E, Margaritis D, **Kotsianidis I**, Georgiou G, Tripsianis G, Anastasiadis A, Karakolios A, Pantelidou D, Panayiotidis P, Bourikas G, Tsatalas C. Long-term bone marrow cultures (LTBMC) from essential thrombocythemia (ET) patients with or without JAK2617V>F mutation. *Leuk Res.* 2008 Mar 3; (IF:2,561)

17. Stakos DA, Margaritis D, Tziakas DN, **Kotsianidis I**, Chalikias GK, Tsatalas K, Bourikas G, Boudoulas H. Cardiovascular involvement in patients with beta-thalassemia major without cardiac iron overload. *Int J Cardiol.* 2008 Jun 16. (IF:4,111)

18. Klepfish A, Rachmilewitz EA, **Kotsianidis I**, Patchenko P, Schattner A. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. *QJM*. 2008 Sep;101(9):737-40. (IF:2,483)
19. **Kotsianidis I**, Bazdiara I, Anastasiades A, Pantelidou D, Margaritis D, Spanoudakis E, Bourikas G, De Coster R, De Porre P, Tsatalas C. In vitro effects of the farnesyltransferase inhibitor tipifarnib on MDS progenitors. *Acta Haematol*; 2008 Sep 30;120(1):51-56. (IF:1,352)
20. **Kotsianidis I**, Bouchliou I, Nakou E, Spanoudakis E, Margaritis D, Christophoridou AV, Anastasiades A, Tsigalou C, Bourikas G, Karadimitris A, Tsatalas C. Kinetics, function and bone marrow trafficking of CD4⁺CD25^{high}Foxp3⁺ regulatory T cells in Myelodysplastic Syndromes (MDS). *Leukemia*. 2009 Mar;23(3):510-8. (IF:8,634)
21. Spanoudakis E, Hu M, Naresh K, Terpos E, Melo V, Reid A, **Kotsianidis I**, A. Rahemtulla A, Karadimitris A. Regulation of multiple myeloma survival and progression by CD1d. *Blood*. 2009 Mar 12;113(11):2498-507. (IF:10,555)
22. Spanoudakis E, Bazdiara I, **Kotsianidis I**, Margaritis D, Goutzouvelidis A, Christoforidou A, Tsatalas C, Bourikas G. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients. *Ann Hematol*. 2009 Jul;88(7):629-32. (IF:2,352)
23. Christoforidou A, Pantelidou D, Anastasiadis A, Goutzouvelidis A, Margaritis D, **Kotsianidis I**, Spanoudakis E, Kaloutsi V, Bourikas G, Tsatalas C. Hydroxyurea and Anagrelide Combination Therapy in Patients with Chronic Myeloproliferative Diseases Resistant or Intolerant to Monotherapy. *Acta Haematol*. 2009 Jan 8;120(4):195-198. (IF:1,352)
24. Stakos DA, Tavridou A, Margaritis D, Tziakas DN, **Kotsianidis I**, Chalikias GK, Tsatalas K, Bourikas G, Manolopoulos VG, Boudoulas H. Oxidised low-density lipoprotein and arterial function in beta-thalassemia major. *Eur J Haematol*. 2009 Jun;82(6):477-83. (IF:2,163)
25. **Kotsianidis I**, Nakou E, Bouchliou E, Tzouvelekis A, Spanoudakis E, Steiropoulos P, Sotiriou I, Aidinis V, Margaritis D, Tsatalas C, Bouros D. Global impairment of CD4⁺CD25⁺foxp3⁺ T regulatory cells in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2009 Jun 15;179(12):1121-30. (IF:9,792)
26. Steiropoulos P, **Kotsianidis I**, Nena E, Tsara V, Gounari E, Hatzizisi O, Kyriazis G, Christaki P, Bouros D. Long term effect of continuous positive airway pressure therapy on the systemic immunity of patients with obstructive sleep apnea syndrome. *Sleep*. 2009 Apr;32(4):537-43. (IF:5,402)
27. Anastasiadis A, Margaritis D, **Kotsianidis I**, Spanoudakis E, Christoforidou A, Kostopoulos I, Tsatalas C. Pure red cell aplasia as first manifestation of splenic marginal zone lymphoma-successful treatment with rituximab: a case report. *Cases J*. 2009 Aug 18;2:6913. (IF:0,35)
28. Klepfish A, Gilles L, **Ioannis K**, Rachmilewitz EA, Schattner A. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. *Ann N Y Acad Sci*. 2009 Sep;1173:865-73. (IF:4,039)

My last name has been inadvertently written as my first name.

29. Kotsianidis I, Goutzouvelidis A, Anastasiades A, Bouchliou I, Nakou E, Spanoudakis E, Christophoridou AV, Margaritis D, Bourikas G, Tsatalas C. Severe thrombocytopenia and fibrinolysis mimicking disseminated intravascular coagulation after rituximab infusion. *Am J Hematol.* 2010 Feb;85(2):146. (IF:4,671)

30. Spanoudakis E, Bazdiara I, Pantelidou D, **Kotsianidis I**, Papadopoulos V, Margaritis D, Xanthopoulidis G, Moustakidis E, Mantzourani S, Bourikas G, Tsatalas C. Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms. *Leuk Res.* 2011 Apr;35(4):459-64. (IF:2,561)

31. Hu M, Bassett JH, Danks L, Howell PG, Xu K, Spanoudakis E, **Kotsianidis I**, Boyde A, Williams GR, Horwood N, Roberts IA, Karadimitris A. Activated invariant NKT cells regulate osteoclast development and function. *J Immunol.* 2011 Mar 1;186(5):2910-7. (IF:6,068)

32. Bouchliou I, Miltiades P, Nakou E, Spanoudakis E, Goutzouvelidis A, Vakalopoulou S, Garypidou V, Kotoula V, Bourikas G, Tsatalas C, **Kotsianidis I**. Th17 and Foxp3(+) T regulatory cell dynamics and distribution in myelodysplastic syndromes. *Clin Immunol.* 2011 Jun;139(3):350-9. (IF:3,893)

33. Vadikolia CM, Tsatalas C, Anagnostopoulos K, Trypsianis G, Pantelidou D, Bazdiara I, Anastasiadis A, Spanoudakis E, **Kotsianidis I**, Margaritis D, Kortsaris A, Bourikas G. Proteolytic matrix metallopeptidases and inhibitors in BCR-ABL1-negative myeloproliferative neoplasms: correlation with JAK2 mutation status. *Acta Haematol.* 2011;126(1):54-62. (IF:1,352)

34. Kotsianidis I, Nakou E, Spanoudakis E, Bouchliou I, Moustakidis E, Miltiades P, Vadikolia CM, Szydlo R, Karadimitris A, Tsatalas C. The diagnostic value of CD1d expression in a large cohort of patients with B-cell chronic lymphoproliferative disorders. *Am J Clin Pathol.* 2011 Sep;136(3):400-8. (IF:2,6)

35. Christoforidou A, **Kotsianidis I**, Margaritis D, Anastasiadis A, Douvali E, Tsatalas C. Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate. *Am J Hematol.* 2012 Jan;87(1):131-2. (IF:4,671)

36. Tzouvelekis A, Koliakos G, Ntoliou P, Baira I, Bouros E, Oikonomou A, Zissimopoulos A, Kolios G, Kakagia D, Paspaliaris V, **Kotsianidis I**, Froudarakis M, Bouros D. Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. *J Transl Med.* 2011 Oct 21;9:182. (IF:3,47)

37. Kotsianidis I, Spanoudakis E, Nakou E, Miltiades P, Margaritis D, Tsatalas C, Tzouvelekis A, Oikonomou A. Hypomethylating therapy and autoimmunity in MDS: An enigmatic relationship. *Leuk Res.* 2012 Apr;36(4):e90-2. (IF:2,561)

38. Nakou E, Babageorgakas P, Bouchliou I, Tziakas DN, Miltiades P, Spanoudakis E, Margaritis D, **Kotsianidis I**, Stakos DA. Statin-Induced Immunomodulation Alters Peripheral Invariant Natural Killer T-cell Prevalence in Hyperlipidemic Patients. *Cardiovasc Drugs Ther.* 2012 Mar 24. (IF:3,13)

39. Papageorgiou SG, Diamantopoulos P, Levidou G, Angelopoulou MK, Economopoulou P, Efthimiou A, Constantinou N, Katsigiannis A, Korkolopoulou P, Pappa V, Economopoulou C, Georgiou G, Dimou M, Tsigotis P, Kyrtsonis MC, **Kotsianidis I**, Kalpadakis C, Dimopoulos

MA, Beris P, Meletis J, Pangalis GA, Dervenoulas J, Panayiotidis P, Vassilakopoulos TP. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. *Hematol Oncol.* 2012 May 18. (IF:2,475)

40. Kambas K, Mitroulis I, Apostolidou E, Girod A, Chrysanthopoulou A, Pneumatikos I, Skendros P, Kourtzelis I, Koffa M, **Kotsianidis I**, Ritis K. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. *PLoS One.* 2012;7(9):e45427. (IF:4,41)

41. Oikonomou A, Astrinakis E, **Kotsianidis I**, Kaloutsi V, Didilis V, Tsatalas K, Prassopoulos P. Synchronous BALT Lymphoma and Squamous Cell Carcinoma of the Lung: Coincidence or Linkage? *Case Rep Oncol Med.* 2013;2013:420393.

42. Chloropoulou P, Iatrou C, Vogiatzaki T, **Kotsianidis I**, Trypsianis G, Tsigalou C, Paschalidou E, Kazakos K, Touloupidis S, Simopoulos K. Epidural anesthesia followed by epidural analgesia produces less inflammatory response than spinal anesthesia followed by intravenous morphine analgesia in patients with total knee arthroplasty. *Med Sci Monit.* 2013 Jan 28;19:73-80. (IF:1,36)

43. Anastasiadis A, **Kotsianidis I**, Papadopoulos V, Spanoudakis E, Margaritis D, Christoforidou A, Gouliamtzi S, and Tsatalas C. CD1d expression as a prognostic marker for chronic lymphocytic leukemia. *Leuk Lymphoma.* 2014 Feb;55(2):320-5. (IF:2,36)

44. Douvali E, Papoutselis M, Vassilakopoulos TP, Papadopoulos V, Spanoudakis E, Tsatalas C, **Kotsianidis I**. Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment. *Leuk Res.* 2013 Aug;37(8):889-93. (IF:2,764)

45. Papoutselis M, Douvali E, Papadopoulos V, Spanoudakis E, Margaritis D, Tsatalas C, **Kotsianidis I**. Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience. *Leuk Res.* 2014 Feb;38(2):161-5. (IF:2,764)

46. Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos AG, Vakalopoulou S, Garypidou V, Papaioannou M, Hadjiharissi E, Pappa V, Papadaki HA, Spanoudakis E, Tsatalas K, **Kotsianidis I**. Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacytidine. *Blood Cancer J.* 2014 Feb 28;4:e187. (IF:3,467)

47. Pavlaki K, Pontikoglou CG, Demetriadou A, Batsali AK, Damianaki A, Simantirakis E, Kontakis M, Galanopoulos A, **Kotsianidis I**, Kastrinaki MC, Papadaki HA. Impaired Proliferative Potential of Bone Marrow Mesenchymal Stromal Cells in Patients with Myelodysplastic Syndromes Is Associated with Abnormal WNT Signaling Pathway. *Stem Cells Dev.* 2014 Apr 21. (IF:4,67)

48. **Kotsianidis I**. Surface antigen expression in CLL: a new member among the mnesteres for the prognosis of bad risk disease. *Leuk Res.* 2014 Apr;38(4):423-4. (IF:2,764)

49. Fouka E, Lamprianidou E, Arvanitidis K, Filidou E, Kolios G, Miltiades P, Paraskakis E, Antoniadis A, **Kotsianidis I**, Bouros D. Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients. *Lung.* 2014 Dec;192(6):849-55. (IF:2,271)

- 50. Kotsianidis I**, Tsatalas C. Sequential development of different acute leukemia types in the same patient. *Blood*. 2014 Oct 16;124(16):2608. (IF:10,452)
- 51.** Oriol A, Giraldo P, **Kotsianidis I**, Couturier C, Olie R, Angermund R, Corso A. Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: a retrospective study. *Hematology*. 2014 Dec 10. (IF:1,253)
- 52.** Vassilakopoulos TP, Pangalis GA, Chatziioannou S, Papageorgiou S, Angelopoulou MK, Galani Z, Kourti G, Prassopoulos V, Leonidopoulou T, Terpos E, Dimopoulou MN, Sachanas S, Kalpadakis C, Konstantinidou P, Boutsis D, Stefanoudaki E, Kyriazopoulou L, Siakantaris MP, Kyrtsolis MC, Variami E, **Kotsianidis I**, Symeonidis A, Michali E, Katodritou E, Kokkini G, Tsatalas C, Papadaki H, Dimopoulos MA, Sotiropoulos V, Pappa V, Karmiris T, Meletis J, Apostolidis J, Datsiris I, Panayiotidis P, Konstantopoulos K, Roussou P, Rondogianni P. PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. *Leukemia*. 2015 May 14. (IF:10,431)
- 53.** Miltiades P, Lamprianidou E, Kerzali IK, Nakou E, Papamichos SI, Spanoudakis E, **Kotsianidis I**. Three-fold higher frequency of circulating chronic lymphocytic leukemia-like B-cell clones in patients with Ph-Myeloproliferative neoplasms. *Leuk Res*. 2015; Aug 14. (IF:2,764)
- 54.** Spanoudakis E, Papoutselis M, Miltiades P, Papamichos SI, Tilkeridis C, Tsatalas C, **Kotsianidis I**. The presence of the JAK2V617F point mutation affects osteoclast function in patients with chronic myeloproliferative neoplasms. *Blood Cells Mol Dis*. 2015; under revision. (IF:2,646)
- 55.** Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos AG, Nakou E, Vakalopoulou S, Garypidou V, Papaioannou M, Hadjiharissi E, Papadaki HA, Spanoudakis E, Pappa V, Tsatalas K, **Kotsianidis I**. The Stat3/5 signaling biosignature in hematopoietic stem/progenitor cells predicts response and outcome in myelodysplastic syndrome patients treated with azacitidine. *Clin Cancer Res* 2015 under revision. (IF:8,722)
- 56.** Tiptiri-Kourpeti A, Spyridopoulou K, Santarmaki V, Aindelis G, Tompoulidou E, Lamprianidou E, Saxami G, Ypsilantis P, Lampri E, Simopoulos C, **Kotsianidis I**, Galanis A, Kourkoutas Y, Dimitrellou D, Chlichlia K. *Lactobacillus casei* exerts anti-proliferative effects accompanied by apoptotic cell death and up-regulation of TRAIL in colon carcinoma cells. *PlosOne* 2015 submitted after revision. (IF:3,2)
- 57.** Skendros P, Papagoras C, Lefaki I, Giatromanolaki A, **Kotsianidis I**, Speletas M, Bocly V, Theodorou I, Dalla V, Ritis K. Successful response in a case of severe pustular psoriasis after IL-1 β inhibition. *Br J Dermatol*. 2016 Apr 23.
- 58.** Arelaki S, Arampatzioglou A, Kambas K, Papagoras C, Miltiades P, Angelidou I, Mitsios A, **Kotsianidis I**, Skendros P, Sivridis E, Maroulakou I, Giatromanolaki A, Ritis K. Gradient Infiltration of Neutrophil Extracellular Traps in Colon Cancer and Evidence for Their Involvement in Tumour Growth. *PLoS One*. 2016 May 2;11(5):e0154484.
- 59.** Papadopoulou V, Kontandreopoulou E, Panayiotidis P, Roumelioti M, Angelopoulou M, Kyriazopoulou L, Diamantopoulos PT, Vaiopoulos G, Variami E, **Kotsianidis I**, Athina Viniou N. Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia. *Leuk Lymphoma*. 2016 May;57(5):1182-8.

60. Pappa V, Anagnostopoulos A, Bouronikou E, Briasoulis E, **Kotsianidis I**, Pagoni M, Zikos P, Tsionos K, Viniou N, Meletis J, Papadaki H, Kioumi A, Galanopoulos A, Vervessou EC, Poulakidas E, Karmas P, Karvounis K, Symeonidis A. A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece. *Int J Hematol*. 2016 Nov 4

Non-indexed (in Medline) Publications

1. **Kotsianidis I**, Nakou E, Bouchliou E. Pharmacotherapy of Hematologic Malignancies with Tipifarnib. *Clinical Medicine: Therapeutics* 2009;1 855–869.

2. Tzouveleakis A, Karameris A, Tsiambas E, Koutsopoulos A, Tringidou R, Froudarakis M, Mikroulis D, Aidinis V, Steiropoulos P, Bazdiara I, Tsatalas C, **Kotsianidis I**, Pneumatikos I, Bouros D. Telomerase in pulmonary fibrosis. A link to alveolar cell apoptosis and differentiation. *Pneumon* 2010, 23(3):224-239.

3. **Kotsianidis I**. Single Cell Phospho-Signaling Analysis in Myeloid Malignancies. *Ann Clin Cytol Pathol* 2014, 1(1): 1001.

4. **Kotsianidis I**, Kokkinou D, Miltiades P, Siapati E, Labrianidou E, Vassilopoulos G, Zoumbos NC, Spyridonidis A. Identification of a chemoresistant “oxidative state-low” leukemic subpopulation in CD34+ human acute myeloid leukemia. *J Stem Cell Res Ther* 2014, 4:235

Invited talks

1. **Successful treatment of angioimmunoblastic lymphoma with fludarabine.** Hellenic Society of Hematology, meeting of the Macedonia-Thrace department. Thessaloniki, November 2000.

2. **Immunological investigation of T cell lymphomas.** One-day meeting of the Hellenic society of Immunology, Alexandroupolis, October 2001.

3. **Concomitant presentation of B-CLL with AML.** Hellenic Society of Hematology, meeting of the Macedonia-Thrace department. Thessaloniki, February 2002.

4. **Immunophenotypic analysis of lymphoproliferative disorders.** 2nd Annual Congress of the Hellenic Society of Flow Cytometry, Rhodes, May 2002.

5. **Immune regulation of haematopoiesis.** 4th Annual Congress of the Hellenic Society of Flow Cytometry, Santorini, May 2006.

6. **Acute myeloid leukemia: future treatments.** Hellenic Society of Hematology, meeting of the Macedonia-Thrace department. Thessaloniki, February 2007.

7. **Study of non-hematopoietic cells with flow cytometry.** One-day meeting of the Hellenic society of Flow Cytometry, Alexandroupolis, May 2007.

8. **Laboratory investigation of haematological malignancies: Flow cytometry.** 18th Annual Congress of the Hellenic Society of Hematology, 2nd Balkan Day of Hematology. Thessaloniki, November 2007.

- 9. Mantle cell lymphoma.** 2nd seminar in Pathology of Lymphomas, Alexandroupolis, April 2008.
- 10. Hepatotropic viruses and lymphomas.** 3^d educational meeting : Progress in Gastroenterology and Hepatology, Alexandroupolis, April 2008.
- 11. Regulation of the tumor immunity.** 5th Annual Congress of the Hellenic Society of Flow Cytometry, Olympia, June 2008
- 12. Emerging immune mechanisms in pulmonary disease: The role of IL-17 and T regulatory cells.** 17th Annual Congress of the Hellenic Thoracic Society, Alexandroupolis, November 2008.
- 13. PET-scan in therapeutical decision making in Hodgkin's lymphoma.** Open day: Hodgkin's lymphoma. Athens, January 2009.
- 14. Therapeutic algorithm in high-risk MDS.** Hellenic Society of Hematology, meeting "Current therapeutic approaches in Myelodysplastic syndromes", Heraklion, February 2009.
- 15. Classification and prognosis of Myelodysplastic syndromes.** 20th Annual Congress of the Hellenic Society of Hematology. Heraklion, November 2009.
- 16. Investigation of signaling profiles of normal and cancer cells by flow cytometry.** 6th Annual Congress of the Hellenic Society of Flow Cytometry, Kefalonia, April 2010.
- 17. Epigenetic alterations in MDS.** Institute of Hellenic Society of Hematology, two-day meeting "Days of Institute of ESH", Alexandroupolis, May 2010.
- 18. Cancer immunology.** 4th Summer School of Oncology, Alexandroupolis, July 2010.
- 19. Mantle cell lymphoma: is it just one disease?** Hellenic Society of Hematology, meeting "Therapeutic progress in Lymphomas", Santorini, October 2010.
- 20. Pathogenesis of MDS and the role of epigenetic alterations.** 19th National Conference of Clinical Hematology and Transfusion Medicine, Sinaia, Romania, October 2010.
- 21. Myelodysplastic syndromes: Classification - Diagnosis - Prognosis.** Hellenic Society of Hematology, meeting "Novel data on pathophysiology, diagnosis and treatment of MDS", Chania, May 2011.
- 22. Flow cytometry and epigenetics.** 6th meeting of the Hellenic Society of Flow Cytometry, Athens, May 2011.
- 23. Treatment of high risk MDS.** 1st Polythematic Conference in Hematology, Cyprus Society of Flow Cytometry. Paphos, Cyprus, July 2011.
- 24. Mantle cell lymphoma. Molecular basis and treatment.** Institute of Hellenic Society of Hematology, two-day meeting "Lymphomas", Heraklion, Crete, September 2011.
- 25. New data on the pathogenesis of MDS.** 22nd Annual Congress of the Hellenic Society of Hematology. Athens, November 2011.
- 26. Immunophenotypic characterization of haematopoietic stem/progenitor cells.** 7th Annual Congress of the Hellenic Society of Flow Cytometry, Athens, May 2012.

- 27. Therapeutic approach and future strategies in intermediate-2/high risk MDS.** Institute of Hellenic Society of Hematology, one-day meeting, Kyllini, June 2012.
- 28. Stem cells: therapeutic properties and donation?** Two-day meeting “Quality assurance in blood banking”, Alexandroupolis, November 2012.
- 29. MDS pathophysiology: Is there a stem cell?** 23^d Annual Congress of the Hellenic Society of Hematology. Thessaloniki, November 2012.
- 30. Azacytidine treatment in a patient with expanded erythropoiesis?** Satellite symposium Genesis Pharma, 23^d Annual Congress of the Hellenic Society of Hematology. Thessaloniki, November 2012.
- 31. Flow cytometry: understanding and indications.** Hematology department of Ioannina, one-day meeting, Ioannina, January 2013.
- 32. Gaucher disease.** One-day meeting of Scientific Society for Rare Diseases & Orphan Drugs, Alexandroupolis, April 2013.
- 33. Treatment of intermediate-2/high risk MDS patients and survival improvement.** Institute of Hellenic Society of Hematology, two-day meeting, Kalamata, April 2013.
- 34. PET/CT+ but negative CT in the end of treatment in a late stage HD patient: next move?** Hellenic Society of Hematology, lymphoma study group one-day meeting, Plastiras lake, April 2013.
- 35. Mechanisms of action of novel biological agents in hematopoiesis.** Satellite symposium Amgen Hellas, 24th Annual Congress of the Hellenic Society of Hematology. Athens, November 2013.
- 36. Mechanisms of production of clinical guidelines and recommendations.** Hematology department of Ioannina and Society of Internal Medicine of Northwest Greece, two-day meeting, Ioannina, January 2014.
- 37. Bad risk CLL.** Hematology two-day meeting of Central Greece, Larissa, March 2014.
- 38. Presentation of the Laboratory of the department of Hematology.** 1st Symposium of Education and Research of the Medical school of Democritus University of Thrace, Alexandroupolis, March 2014.
- 39. BiTE biotechnology in the treatment of acute lymphoblastic leukemia.** One-day meeting: Treatment approaches in B-cell malignancies, Thessaloniki, May 2014.
- 40. 5-azacytidine for the treatment of elderly patients.** 3^d seminar in Hematology, Satellite symposium Genesis Pharma, Ioannina, October 2014.
- 41. MDS cases.** one-day meeting of the Hellenic MDS study group, Bridge meeting Celgene, Nafplio, October 2014.
- 42. The progress in G-CSF structure and differences in their preclinical characteristics.** 25th Annual Congress of the Hellenic Society of Hematology, Satellite symposium TEVA Hellas, Thessaloniki, November 2014.

43. The clinical experience in the management of adult chronic ITP. 25th Annual Congress of the Hellenic Society of Hematology, Satellite symposium Glaxo Hellas, Thessaloniki, November 2014.

44. Mechanisms and possible ways of overcoming resistance in hypomethylating agents. 25th Annual Congress of the Hellenic Society of Hematology. Thessaloniki, November 2014.

45. Monoclonal antibodies in the treatment of CLL. Hematology two-day meeting of Central Greece, Larissa, February 2015.

46. Challenges and dilemmas in the treatment of elderly MDS patients. 1st Panhellenic Congress of continuing education in internal medicine with international participation, Satellite symposium Genesis Pharma, Thessaloniki, February 2015.

47. Treatment of MDS patients after azacytidine failure. One-day meeting: Treatment of hematological malignancies with disease-modifying agents, Kalabaka, April 2015.

48. Therapeutic progress-emerging treatments in Lymphomas. 15th Panhellenic Congress of Radiation oncology, Thessaloniki, May 2015.

49. Presentation of the Laboratory of the department of Hematology. 2nd Symposium of Education and Research of the Medical school of Democritus University of Thrace, Alexandroupolis, May 2015.

50. Current treatment of MDS. Hellenic Society of Hematology, meeting of the Macedonia-Thrace department. Thessaloniki, May 2002.

Awards

- 1. Velcade affects antigen presentation of proteasome-depending epitopes. Need for antiviral prophylaxis.** Best poster award, 16th Annual Congress of the Hellenic Society of Hematology. Athens, November 2005.
- 2. The role of naturally occurring CD4+CD25+ T regulatory cells in the pathogenesis of Idiopathic Interstitial Pneumonias.** Clinical research award, 16th Annual Congress of the Hellenic Thoracic Society, Athens, November 2007.
- 3. Alterations in number, function and trafficking of CD4⁺CD25^{high}Foxp3⁺ T regulatory cells contribute to MDS pathogenesis.** Young investigator award, 18th Annual Congress of the Hellenic Society of Hematology, Thessaloniki, November 2007.
- 4. Study of the dynamics of telomere length and telomerase activity in ph-negative myeloproliferative neoplasms.** Best oral presentation, 18th Annual Congress of the Hellenic Society of Hematology, Thessaloniki, November 2007.
- 5. From lipidemia to atherosclerosis: The role of iNKT cells and the effect of statins.** Third award in the 4th Annual Congress of Atherosclerosis, Athens, February 2008.
- 6. Defects in T cell regulation reveal distinct pathogenetic pathways in ILD.** Bursary for the 6th ERS Lung Science Conference, Estoril, March 2008.
- 7. Impaired T cell regulation in idiopathic pulmonary fibrosis.** Best poster award, 17th Annual Congress of the Hellenic Thoracic Society. Alexandroupolis, November 2008.

8. **The role of invariant Natural killer T cells (iNKT) in normal osteoclastogenesis and in bone disease of multiple myeloma (third author).** Young investigator award, 21st Annual Congress of the Hellenic Society of Hematology, Thessaloniki, November 2010.
9. **The role of JAK2 kinase in osteoclast function in patients with myeloproliferative neoplasms.** Best oral presentation, 22nd Annual Congress of the Hellenic Society of Hematology, Athens, November 2011.
10. **Identification of a GCSF-inducible subpopulation of clonal MDS progenitors with leukemia stem cell characteristics: a new biomarker of response to azacitidine.** “Arkagathos Goutas” award, 23^d Annual Congress of the Hellenic Society of Hematology, Thessaloniki, November 2012. Of note, this is the most prestigious award of the Hellenic Society of Hematology.
11. **Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway.** “Arkagathos Goutas” award, 24th Annual Congress of the Hellenic Society of Hematology, Athens, November 2013.
12. **Distinct epigenetic modulation of stat signaling in FOXP3+ T regulatory cells (TREGS) of CMML- 2 patients.** Nomination “six best abstracts” in the 4th International Conference on Myelodysplastic Syndromes, Estoril, May 2014.
13. **Retrotransposon exaptation coupled with adaptive evolution significantly contributed to the generation of a human-protein-specific coding gene that promotes cancer cell proliferation and metastasis in various tumours: the case of MYEOV gene.** 14. EMBL Fellowship in EMBO | EMBL Symposium: The Mobile Genome: Genetic and Physiological Impacts of Transposable Elements, Heidelberg, September 2015.

TEACHING EXPERIENCE

- 03/97-11/98: Clinical training of 6th (last) year medical students at the Hippokraton General Hospital of Thessaloniki.
- 01/99-12/02: Clinical training on the ward of 6th (last) year medical students at the University Hospital of Alexandroupolis.
- 01/01-12/02: Seminar lectures at postgraduate programs for nursing personnel.
- 03/03-05/05: Supervision of two BSc students (both completed their thesis) in the laboratory of Professor Irene Roberts, Faculty of Medicine –ICSTM, Hammersmith Hospital, London UK.
- 05/05-to date: Teaching of Hematology in 5th year medical students (compulsory). Democritus University of Thrace, Medical School, Alexandroupolis, Greece.
- 05/05-to date: Supervision of 22 BSc students of the Department of Molecular Biology and Genetics, Democritus University of Thrace (18 completed their graduate diploma thesis)
- 05/05- to date: Seminar lectures in registrars in Hematology at the University Hospital of Alexandroupolis.
- 01/07-to date Seminar lectures on Flow Cytometry in 3^d year students of Molecular Biology and Genetics (MBG), Democritus University of Thrace.
- 03/07-03/14: Seminar courses at the postgraduate program “Clinical Pharmacology”. Democritus University of Thrace, Medical School, Alexandroupolis. Lectures on growth factors, ferrum metabolism, vitamins, anticoagulants, epigenetic treatments.
- 04/08-to date: Supervision of 5 PhD students of the Democritus Thrace University, Medical School, Alexandroupolis. (One completed his thesis with grade “excellent”, one has received the prestigious award “ Arkagathos Goutas” and another one has received the “nomination “six best

- abstracts” at the 4th International Conference on Myelodysplastic Syndromes”). Member of the three-member standing committee in 9 more PhD students of either Democritus Thrace University or other Greek institutions
- 2009 Invited lecture at the postgraduate courses of the department of Cardiology of University Hospital of Alexandroupolis.
- 2008-9 Invited lectures at the postgraduate courses "Lymphomas" of the department of Pathology of University Hospital of Alexandroupolis.
- 11/10- to date: Seminar courses at the postgraduate program of Hellenic Society of Hematology. I am also member of the scientific committee for the education in Hematology (Hellenic Society of Hematology).
- 2010 Invited lecture at the postgraduate course "4th Summer School of Oncology" of the department of Oncology of University Hospital of Alexandroupolis.
- 2011 Invited lecture at the postgraduate courses of the department of Critical Care Medicine of University Hospital of Alexandroupolis.
- 01/12- to date: Teaching of Clinical immunology in 5th year medical students (optionary). Democritus Thrace University, Medical School, Alexandroupolis, Greece
- 2012 Tutor at the workshop “Acute Myeloid leukemia. Flow Cytometry” of the postgraduate program of the Institute of Hellenic Society of Hematology. University Hospital of Herakleion, Crete, Greece.
- 2012 Tutor at the international postgraduate course “Chronic lymphocytic Leukemia.” University Hospital of Herakleion, Crete, Greece.
- 2013 Tutor at the workshop “Myeloproliferative syndromes.” of the postgraduate program of the Institute of Hellenic Society of Hematology. Alexandroupolis, Greece.
- 2013 Tutor at the workshop “Myelodysplastic syndromes: flow cytometry” of the postgraduate program of the Institute of Hellenic Society of Hematology. University Hospital of Herakleion, Crete, Greece.
- 2013 Tutor at the two-day education meeting “Chronic myeloid Leukemia” of the postgraduate program of the Hellenic association for molecular cancer research. Thessaloniki, Greece.
- 2014 Tutor at the two-day education meeting “Chronic lymphocytic Leukemia - MRD” of the postgraduate program of the Hellenic association for molecular cancer research. Thessaloniki, Greece.
- 2014 Tutor on the workshop “Acquired anemias” of the postgraduate program of the Institute of Hellenic Society of Hematology. University Hospital of Herakleion, Crete, Greece.
- 2015 Tutor at the workshop “Investigation of isolated neutropenia.” of the postgraduate program of the Institute of Hellenic Society of Hematology. Alexandroupolis, Greece.

EDITORIAL ACTIVITIES

Ad hoc Reviewer for the National Institute of Scholarships (IKY). Years 2012-3.

Abstract Reviewer for the Annual Congress of the Hellenic Society of Hematology. Years 2008-14. Member of the review board for the “Arkagathos Goutas” and “Faedon Fessas” awards at the 26th Annual Congress of the Hellenic Society of Hematology

Editor of Haema, education book of the 25th Annual Congress of the Hellenic Society of Hematology, November 2014.

Member of editorial board

1. Journal of Hematological Malignancies
2. World Journal of Translational Medicine
3. American Journal of Internal Medicine

Ad hoc Reviewer for scientific journals

1. Haematologica
2. Clinical Cancer Research
3. British Journal of Hematology
4. Experimental Hematology
5. Leukemia Research
6. Annals of hematology
7. Journal of Hematology & Oncology
8. Acta Haematologica
9. Plos One
10. Clinical immunology
11. Expert Opinion On Investigational Drugs
12. Human immunology
13. Journal of Clinical Immunology and Immunopathology Research
14. Cancer immunology immunotherapy
15. Cytokine
16. American Journal of Respiratory and Critical Care Medicine
17. Respiratory Research
18. Pneumon
19. Pulmonary medicine
20. Gene Therapy and Molecular Biology
21. Journal of Medical Case Reports
22. Advances in Genomics and Genetics
23. Journal of Blood Medicine
24. Journal of Drug Delivery
25. Turkish Journal of Hematology
26. Hippokratia

ADMINISTRATION

Administration of clinical departments/laboratories

- 1 Head of the Laboratory of Hematology and Immunoematology of Democritus university of Thrace.
- 2 Associate director of the Hematology department of the university Hospital of Alexandoupolis.

Member of scientific societies and committees

- 1 Member of the Hellenic Society of Hematology.
- 2 Member of the Hellenic Society of Flow Cytometry.
- 3 Member of the American Society of Hematology (ASH).
- 4 Elected member of the steering committee of the Hellenic MDS Study Group.
- 5 Member of the scientific education committee of the Hellenic Society of Hematology.

Conference organizer

- 1 Member of the organizing committee of the 2nd Annual Congress of the Hellenic Society of Flow Cytometry, Rhodes, May 2002.
- 2 Member of the organizing committee of the 2nd Annual Congress of the Hellenic Society of Flow Cytometry, Rhodes, Kephallonia 2010.
- 3 Member of the scientific committee of the 22nd Annual Congress of the Hellenic Society of Hematology, Athens, November 2011.
- 4 Vice president of the scientific committee of the 7th Annual Congress of the Hellenic Society of Flow Cytometry, Athens, May 2012.
- 5 Member of the organizing committee of the 1st Symposium of Education and Research of the Medical school of Democritus University of Thrace, Alexandroupolis, March 2014.
- 6 Member of the organizing committee of the 8th Annual Congress of the Hellenic Society of Flow Cytometry, Athens, October 2014.
- 7 Member of the organizing committee of the 2nd Symposium of Education and Research of the Medical school of Democritus University of Thrace, Alexandroupolis, May 2015.

NARRATIVE REPORT

I am a Hematologist devoting approximately 40% of my time to the care of patients with hematological malignancies, in particular Myelodysplastic syndromes, and 40% of my time to research, primarily translational. The remainder of my time is filled by teaching and administrative responsibilities.

My research interests are focused on the immune regulation and cell signaling interactions of normal and malignant hematopoiesis. I perform primarily translational research investigating novel biomarkers of response and mechanisms of resistance to hypomethylating agents. The first study is almost completed and has received the highest award (“Arkagathos Goutas”) at the 23^d Annual Congress of the Hellenic Society of Hematology. During my training in the laboratory of Professor Irene Roberts and Dr Anastasios Karadimitris in Hammersmith Hospital, London, I participated and in the discovery of the mutation responsible for the inherited paroxysmal nocturnal hemoglobinuria, whereas my research team was the first to report the regulation of normal haematopoiesis by the invariant NKT cells. In my laboratory in Greece I kept up on the same field and our novel data on the involvement of FOXP3+ T regulatory cells in the pathobiology of MDS gained wide recognition and were cited in the most prestigious journal of clinical medicine, the New England JM. I am currently organizing a registry of patients with various hematological malignancies in the University Hospital of Alexandroupolis and the first retrospective studies on MDS have already been published. Of note, my research is based on patient material from all over Greece via an extensive network of collaborating research groups, whereas I closely collaborate with prestigious international research networks, such as the Groupe Franco-phone des Myelodysplasies (GFM) and the International Working Group for Prognosis in MDS (IWG-PM). In addition my laboratory supports numerous projects from various departments of the University Hospital of Alexandroupolis, i.e. Pneumonology, Nephrology, Cardiology, Orthopedics and Internal Medicine departments.

I have extensive teaching activities that include a wide spectrum of thematologies taught in undergraduate and postgraduate students and specialist Haematologists. Most of my teaching themes pertain to MDS pathobiology and treatment and to flow cytometry techniques.

As regards my editorial and administrative duties I am an elected member of the steering committee of the Hellenic MDS Study Group and also a member of various local and international scientific societies. Moreover, I serve as a reviewer in 26 scientific journals in the fields of Hematology, Immunology, pharmacology, molecular biology and Pneumonology and I am actively involved in the organization of various meetings and Congresses, whereas I

am also the head of the ImmunoHematology laboratory of University Hospital of Alexandroupolis and I manage several clinical and research protocols.

Sincerely,

Ioannis Kotsianidis MD, PhD
Professor of Hematology